The effect of chronic renal failure on drug metabolism and transport

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 8, 2008, Pages 1065-1074

  Dreisbach, Albert W ^a   Lertora, Juan J L ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chronic renal failure; CYP; Cytochrome P450; Drug transport; Efflux transporters; Hepatic clearance; P glycoprotein; Uremic toxins

Indexed keywords

AMINOPHENAZONE; CAPTOPRIL; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C11; CYTOKINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; ERYTHROMYCIN; GLYCOPROTEIN P; IMIPENEM; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; NICARDIPINE; NIMODIPINE; NORDAZEPAM; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; OXPRENOLOL; PARATHYROID HORMONE; PROCAINAMIDE; PROPRANOLOL; SULFAFURAZOLE; UNINDEXED DRUG; VERAPAMIL; WARFARIN; ZIDOVUDINE;

CHRONIC KIDNEY FAILURE; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG LABELING; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME METABOLISM; HEMODIALYSIS; HUMAN; LIVER CLEARANCE; LIVER METABOLISM; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; REVIEW;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DOWN-REGULATION; HUMANS; KIDNEY FAILURE, CHRONIC; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

ANIMALIA;

EID: 51049095076     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.8.1065     Document Type: Review

References (93)

1. Reidenberg MM. Chapter 3, Drug metabolism in uremia, in renal function and drug action. Philadelphia, Saunders; 1971:19-32
2. Gibson TP. Renal disease and drug metabolism: an overview. Am J Kidney Dis 1986;8(1):7-17
3. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP Ann Pharmacother 1991;25:1214-24
4. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Brit J Anaesth 1993;71:282-90
5. Talbert RL. Drug dosing in renal insufficiency. J Clin Pharmacol 1994;34:99-110
6. Lam YW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997;32:30-57
7. Dreisbach AW, Lertora JJL. The effect of chronic renal failure on hepatic metabolism and drug disposition. Semin Dial 2003;169:45-50
8. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 2003;42:906-25
9. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab 2003;4:91-103
10. Sun H, Frasseto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Therap 2006;109:1-11
11. Nolin TD, Naud J, Leblond FA, et al. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83(6):898-903
12. Rowland M, Tozer TN. Chapter 11 Elimination. Clinical pharmacokinetics. In: Malvern PA, editor, 2nd edition. Lea and Febiger; 1989. p. 148-76
13. Reidenberg MM, Drayer DE. Alterations of drug protein binding in renal disease. Clin Pharmacokinet 1984;9(Suppl 1):18-26
14. Ochs HR, Rauh HW, Greenblatt DJ, et al. Chlorazepate dipotassium and Diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron 1984;37:100-4
15. Andreasen F. Protein binding of drugs in plasma from patients with acute renal failure. Acta Pharmacol Toxicol 1973;32:417-29
16. Hooper WD, Bochner F, Eadie MJ. Plasma protein binding of diphenylhydantion: effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1991;49:457-67
17. Reidenberg MM, Odar-Cederlof I, Von Bahr C, et al. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Eng J Med 1971;285:264-7
18. Farrell PC, Grib NL, Fry DL, et al. A comparision of in vitro and in vivo solute-protein binding interactions in normal and uraemic subjects. Trans Am Soc Artfic Intern Organs 1972;18:268-76
19. Lowenthal DT, Briggs WA, Lev G. Kinetics of salicylate elimination in anephric patients. J Clin Invest 1974;54:1221-6
20. Andreasen F, Jakobsen P. Determination of frusemide in blood plasma and its binding to proteins in normal plasma and in plasma of patients with acute renal Failure. Acta Pharmacol Toxicol 1974;35:49-57
21. Rane A, Villeneuve JP, Stone WJ, et al. Plasma binding and distribution of frusemide in the nephrotic syndrome and uraemia. Clin Pharmacol Ther 1978;24:199-207
22. Bachmann K, Shapiro R, Mackiewicz J. Influence of renal dysfunction on warfarin plasma protein binding. J Clin Pharmacol 1976;16:168-72
23. Belpaire FM, Bogaert MG, Mussche MM. Influence of renal failure on the protein binding of drugs in animals and man. Eur J Clin Pharmacol 1977;11:27-32
24. Haughey DB, Kraft CJ, Matzke GR, et al. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 1985;5:35-9
25. Tan CC, Lee HS, Ti TY, Lee EJ. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit 1990;12:29-34
26. Koch-Weser J, Sellers EM. Binding of drugs to serum albumin [2 parts]. N Eng J Med 1976;294:311-6, 526-531
27. Dromgoole SH. The binding capacity of albumin and renal disease. J Pharmacol Exp Ther 1974;191:318-23
28. Anders MW. Metabolism of drugs by the kidney. Kidney Int 1980;18:636-47
29. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90
30. Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther 2000;38:245-53
31. Leblanc M, Roy LF, Villeneuve JP, et al. Liver blood flow in chronic hemodialysis patients. Nephron 1996;73:396-402
32. Amidon GL, Lennernas H, Shah VP, Crison J. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
33. Leber HW, Schutterle G. Oxidative drug metabolism in liver microsomes from uremic rats. Kidney Int 1972;2:152-8
34. VanPeer AP, Belpaire FM. Hepatic oxidative drug metabolism in rats with experimental renal failure. Arch Int Pharmacodyn Ther 1977;228:180-3
35. Leber HW, Gleumes L, Schutterle G. Enzyme induction in the uremic liver. Kidney Int 1978;13(Suppl 8):S43-8
36. Patterson SE, Cohn VH. Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem Pharmacol 1984;33(5):711-6
37. Terao N, Shea DD. Effect of experimental renal failure on the disposition kinetics of 1-propranolol in rats. J Pharmacol Exp Ther 1983;227(2):295-301
38. Terao N, She DD. Reduced extraction of 1-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther 1985;233:277-84
39. Uchida N, Kurata N, Shimada K, et al. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol 1995;68:431-9
40. Leblond FA, Groux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000;(11):1317-20
41. Leblond F, Geuvin C, Demers C, et al. Down regulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001;12:326-32
42. Okabe H, Hasunuma M, Hashimoto Y. The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm Res 2003;20(10):1591-4
43. Geuvin C, Michaud J, Naud J, et al. Down-regulation of hepatic cytochrome P450 in chronic renal failure. Br J Pharmacol 2002;137:1039-46
44. Michaud J, Dube P, Naud J, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrame P450. Br J Pharmacol 2005;144:1067-77
45. Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metabol 2004;5:235-43
46. Abdel-Razzak Z, Loyer P, Fautrel A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Molec Pharmacol 1993;44:707-15
47. Michaud J, Naud J, Choinard J, et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2006;17:3041-8
48. Leblond FA, Pertucci M, Dube P, et al. Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2002;13:1579-15
49. Yoshida T, Kurella M, Beato F, et al. Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int 2002;61:1646-54
50. Reidenberg MM, Kostenbauder H, Adams WP. Rate of drug metabolism in obese volunteers before and during starvation and azotemic patients. Metabolism 1969;18(3):209-13
51. Duchin KL, Pierides AM, Herald A, et al. Elimination kinetics of captopril in patients with renal failure. Kidney Int 1984;25:942-7
52. Kripalani KJ, McKinstry DN, Singhvi SM, et al. Disposition of captopril in normal subjects. Clin Pharmacol Ther 1980;27:636-41
53. Gibson TP, Demetriades JL, Bland JA. Imipenem/cilastin: pharmacokinetic profile in renal insufficiency. Am J Med 1985;78:54-61
54. Gibson TP, Atkinson AJ Jr, Matusik E, et al. Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 1977;12:422-9
55. Lehman CR, Heironimus JD, Collins CB, et al. Metochlopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clin Pharmacol Ther 1985;37:284-9
56. Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet 1983;8:523-9
57. Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ. Clorazepate dipotassium and diazepam in renal insufficiency: Serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron 1984;37:100-4
58. Ochs HR, Greenblatt DJ, Kaschell HJ, et al. Diazepam kinetics in patients with renal isufficiency or hyperthyroidism. Br J Clin Pharmacol 1981;12:829-32
59. Kirch W, Ramsch KD, Duhrsen U, Ohnhaus EE. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res 1984;4:381-4
60. Storstein L, Larsen A, Midtbo K, Saevareid L. Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. Acta Med Scand 1984;216(Suppl 681):25-30
61. Mooy J, Schols M, Baak MV, et al. Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharamcol 1985;28:405-10
62. Gibson TP, Giacomini KM, Briggs WA, et al. Propoxyphene in normal subjects and anephric patients. J Clin Pharmacol 1978;18:106-9
63. Kanfer A, Stamatakis G, Torlotin JC, et al. Changes in erythromycin clearance induced by renal failure. Clin Neprhol 1987;27:147-50
64. Wellling PG, Craig WA. Pharmacokinetics of intravenous erythromycin. J Pharm Sci 1987;67:147-50
65. Bianchetti G, Graziani G, Brancaccio D, et al. Pharmacokinetics and the effects of propranolol in terminal uremic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1976;1:373-84
66. Wood AJJ, Vestal RE, Spannuth CL, et al. Prapranolol disposition in renal failure. Br J Clin Pharmacol 1980;10:561-6
67. Ahmed JH, Grant AC, Rodger RSC, et al. Inhibitory effect of uraemia an hepatic drug clearance and metabolism of nicardapine. Br J Clin Pharmacol 1991;32(1):57-62
68. Frye RF, Matzke GR, Alexander ACM, et al. Effect of renal insufficiency on CYP [abstract]. Clin Pharmacol Ther 1996;59:155
69. Kevorkian JP, Michel C, Hoffmann U, et al. Assessment of individual CYP2D6 in extensive metabolizers with renal failure comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 1996;59:583-92
70. Dreisbach AW, Japa S, Gebrekal AB, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003;73:475-7
71. Dowling TC, Briglia AE, Fink JC. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003;73:427-34
72. Singlas E, Pioger JC, Taburet AM, et al. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 1989;46:190-7
73. Osborne R, Joel S, Grebenik K, et al. The pharmacokinetics of morphine and Morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993;54:158-67
74. Reidenberg MM, Levy M, Drayer DE, et al. Acetylator phenotype in idiopathic systemic lupus etythematosus. Arthritis Rheum 1992;23:569-73
75. Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 1993;54:612-20
76. Simard E, Naud J, Michaud J, et al. Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol 2008;19(7):1352-9
77. Yamazaki M, Akiyama S, Nihisgaki R, Sugiyama Y. Uptake is rate limiting in the overall heparic elimination of pravastatin at steady-state in rats. Pharm Res 1996;13:1559-64
78. Wang H, Le Cluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolizing enzymes. Clin Pharmacokinet 2003;42(15):1331-57
79. Laoari D, Yang R, Veau C, et al. Two apical multidrug transporters, Pgp and MRP2, are altered by chronic renal failure. Am J Physiol 2001;280:F636-45
80. Naud J, Michaud J, Leblond FA, et al. Effects of chronic renal failure on liver drug transporters. Drug Metab Disp 2008;36:124-8
81. Huang ZH, Murakami T, Okochi A. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol 2000;406:453-60
82. Ji L, Masuda S, Saito H, Inui KI. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kid Int 2002;62:514-24
83. Naud J, Michaud J, Boisvert C, et al. Down-regulation of intestinal drug trans-porters in chronic renal failure in rats. J Pharmacol Exp Ther 2007;320:978-85
84. Veau C, Leroy C, Banide H, et al. Effect of chronic renal failure an the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant 2001;16:1607-14
85. Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Dnsg Metab Disp 2004;32:1239-46
86. Aoyama I, Eonomot A, Niwa T. Effects of oral adsorbent on gene expression in uremic rat kidney:cDNA array analysis. Am J Kidney Dis41(S1):S8-14
87. Deguchi T, Ohtsuki S, Otagiri M, et al. Major role organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 2002;61:1760-8
88. Deguchi T, Kusuhara H, Takadate A, et al. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 2004;65:162-74
89. Frassetto LA, Poon S, Tsourounis C, et al. Effects of uptake and efflux transporter inhibition on erythromycin breath test resuts. Clin Pharmacol Ther 2007;81:828-32
90. Nolin TD, Appiah K, Kendrick SA, et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006;17:2363-7
91. Nolin TD, Frye RF, Sadr H, et al. The pharmacokinetics of fexofenadine but not midazolam are altered in end-stage renal disease [abstract]. Clin Pharm Therap 2008;83(S1):S58
92. Vinik HR, Reves JG, Greenblatt DJ, et al. The pharmacokinetics of midazolam in chronic renal failure patients. Anethesiology 1983;59:390-4
93. Huang S, Abraham S, Apparaju S, et al. Impact of the 1998 renal guidance on recent new drug application submissions [abstract]. Clin Pharm Therap 2008;83(S1):S85